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Abstract 
Background: A promising novel cell‑free bioactive formulation for articular cartilage regeneration, called BIOF2, has 
recently been tested in pre‑clinical trials. The aim of the present study was to evaluate the efficacy and safety of BIOF2 
for intra‑articular application in patients with severe osteoarthritis of the knee.
Methods: A prospective, randomized, 3‑arm, parallel group clinical trial was conducted. It included 24 patients with 
severe osteoarthritis of the knee (WOMAC score 65.9 ± 17). Before they entered the study, all the patients were under 
osteoarthritis control through the standard treatment with nonsteroidal anti‑inflammatory drugs (NSAIDs), prescribed 
by their family physician. Patients were distributed into three groups of 8 patients each (intra‑articular BIOF2, total 
joint arthroplasty, or conservative treatment with NSAIDs alone). The WOMAC score, RAPID3 score, and Rasmussen 
clinical score were evaluated before treatment and at months 3, 6, and 12. BIOF2 was applied at months 0, 3, and 6. 
Complete blood count and blood chemistry parameters were determined in the BIOF2 group before treatment, at 
72 h, and at months 1, 3, 6, and 12. In addition, articular cartilage volume was evaluated (according to MRI) at the 
beginning of the study and at month 12.
Results: The NSAID group showed no improvement at follow‑up. Arthroplasty and BIOF2 treatments showed 
significant improvement in all the scoring scales starting at month 3. There were no statistically significant differ‑
ences between the BIOF2 group and the arthroplasty group at month 6 (WOMAC score: 19.3 ± 18 vs 4.3 ± 5; P = 0.24) 
or month 12 (WOMAC score: 15.6 ± 15 vs 15.7 ± 17; P = 1.0). Arthroplasty and BIOF2 were successful at month 12 
(according to a WOMAC score: ≤ 16) in 75% of the patients and the daily use of NSAIDs was reduced, compared with 
the group treated exclusively with NSAIDs (RR = 0.33, 95% CI 0.12–0.87, P = 0.02. This result was the same for BIOF2 vs 
NSAIDs and arthroplasty vs NSAIDs). BIOF2 significantly increased the articular cartilage by 22% (26.1 ± 10 vs 31.9 ± 10 
 cm2, P < 0.001) and produced a significant reduction in serum lipids. BIOF2 was well tolerated, causing slight‑to‑mod‑
erate pain only upon application.
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Background
Osteoarthritis is a chronic disorder of the synovial joints. 
There is progressive softening and disintegration of 
articular cartilage [1], and it is the most common form 
of arthritis. The prevalence of osteoarthritis is on the rise 
and will increase in the coming decades, due to longev-
ity and the growing prevalence of obesity [2]. By the age 
of 65, approximately 80% of the population may present 
with the disease [3]. The knee joint is the most frequently 
affected, followed by the hip and hand joints [4]. It is the 
primary cause of disability and impaired quality of life in 
the elderly [3]. In addition to producing intense pain, it 
affects mobility, mood, and sleep patterns, and reduces 
physical fitness, which can result in an increased risk of 
cardiometabolic comorbidity [3, 5–7].
Despite the considerable medical necessity, no treat-
ment has yet been proven to act as a disease-modifying 
agent that can halt or reverse the structural progression 
of osteoarthritis. Apart from education and exercise, 
the only available non-surgical treatments are directed 
at symptoms—primarily alleviating pain and enhancing 
daily activities and quality of life [8, 9].
When conservative therapy is ineffective in severe cases 
of osteoarthritis of the knee, total joint arthroplasty, in 
which the joint is substituted with a prosthesis, is recom-
mended. However, it is an expensive surgical treatment 
[10] and often entails unacceptably long waiting periods. 
The risk for serious adverse events following total joint 
arthroplasty is low, but perioperative risks can be high in 
elderly patients or those with comorbidities. Good out-
come in total joint arthroplasty is achieved in only half 
of patients presenting with multiple troublesome joints 
and comorbidity, and arthroplasty is not recommended 
in young patients, because the artificial implant has a 
finite lifespan (usually 10–15 years) [11]. Therefore, it is a 
procedure that should only be carried out after a rigorous 
risk–benefit assessment [12].
In recent years, there has been a search for new phar-
macologic therapy regimens. Antidepressants, nonsteroi-
dal anti-inflammatory drugs (NSAIDs), and opiates are 
administered orally, as well as other substances, whose 
benefits have been limited or null, such as glucosamine, 
chondroitin sulfate, methylsulfonylmethane, or collagen 
hydrolysates. Intra-articular injections of corticosteroids 
produce only short-term benefits of significant improve-
ment. Hyaluronic acid derivatives have apparent effec-
tiveness between 5 and 13  weeks after treatment. They 
offer lower efficacy than steroids in the short term, but 
their benefits may increase over a period of weeks and 
can be effective for up to 6  months [13]. Platelet-rich 
plasma (PRP) is being considered as an innovative and 
promising tool, with an effectiveness pattern comparable 
to that of the intra-articular administration of hyaluronic 
acid [14]. The use of scaffolds alone, or in combination 
with stem cells or gene therapy, is strategies that are cur-
rently under development [1, 11].
An innovative concept is the creation of novel cartilage 
in a damaged joint through the administration of cell-free 
bioactive substances that promote chondrogenesis. That 
idea is based on the fact that the fluid inside the joint 
contains mesenchymal cells (MSCs) that are able to dif-
ferentiate into chondrocytes [15].
A promising novel bioactive formulation for articular 
cartilage regeneration, called BIOF2, has recently been 
tested in pre-clinical trials [16]. The intra-articular appli-
cation of BIOF2 significantly increased cartilage thick-
ness (12–38%) in various animal models, compared with 
articular cartilage treated with saline [17]. In addition, 
the articular area and number of chondrocytes increased 
significantly, maintaining an unaltered chondrocyte/mm2 
proportion. Evaluation of the histologic architecture also 
displayed a decrease in the grade of articular damage in 
the animals treated with BIOF2 [17]. Therefore, the pro-
posed hypothesis is that the intra-articular application of 
BIOF2 in humans can induce cartilage formation in joints 
with severe osteoarthritis, resulting in a safe alternative 
to total joint arthroplasty. The aim of the present study 
was to evaluate the efficacy and safety of the intra-artic-
ular application of BIOF2, in patients with severe osteo-
arthritis of the knee, through a randomized, prospective, 
and comparative study.
Methods
Study design
We conducted a prospective, randomized, simple-blind, 
3-arm, parallel group, phase I–II clinical trial between 
Conclusions: The intra‑articular application of the new bioactive cell‑free formulation (BIOF2) was well tolerated and 
showed no significative differences with arthroplasty for the treatment of severe osteoarthritis of the knee. BIOF2 can 
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November 2015 and October 2017. The study was carried 
out according to the “CONSORT statement” guidelines 
for randomized controlled trials.
The present study was approved by the ethics com-
mittee of the Cancerology State Institute of the Health 
Services of the State of Colima, Mexico, and written 
informed consent was obtained from all the participants. 
The present clinical trial was registered as ARTROTX: 
RPCEC00000250 in the Cuban Public Registry of Clini-
cal Trials (RPCEC) Database. The RPCEC trial registra-
tion data set is part of the data set of the International 
Platform Registry as established by the World Health 
Organization (WHO) and the International Committee 
of Medical Journal Editors.
Study subjects
The following inclusion criteria were used: 
patients ≥ 50  years of age, with a body mass index 
(BMI) ≤ 35  kg/m2, and presenting with osteoarthritis 
in one knee, according to the diagnostic criteria of the 
American College of Rheumatology [18], with a Western 
Ontario and McMaster Universities Osteoarthritis Index 
(WOMAC) score > 39, despite conservative therapy [19]. 
A WOMAC score ≥ 39 has been reported as an appro-
priate criterion for total knee replacement [20]. To be 
included in the trial, patients had to be under the stand-
ard conservative treatment (NSAIDs) by their family 
physician, with significant symptoms and/or functional 
limitations associated with reduced health-related quality 
of life. The following exclusion criteria were used: having 
undergone intra-articular treatment within 12  months 
prior to the study, a history of knee trauma or knee sur-
gery, genu varum or genu valgum malalignment (greater 
than 20°), inflammatory polyarthritis or fibromyalgia or 
chronic fatigue syndrome, thromboembolic disease, or 
hemorrhagic blood disease; Hb < 80  g/L; neuromuscular 
disease, cancer, or metabolic bone disease; alcoholism 
and/or drug addiction; or an American Society of Anes-
thesiologists anesthesia rating > 3. The participants were 
recruited from a secondary healthcare center (Centro 
Hospitalario Union in the city of Villa de Álvarez) located 
in the State of Colima, Mexico.
Twenty-four patients were allocated to the intra-artic-
ular BIOF2 group, the total joint arthroplasty group, or 
the group continuing with the standard conservative 
treatment (NSAIDs) prescribed by their family physi-
cian. Randomization was performed using a computer-
generated set of scratch cards, with blocks of 8 and a 
1∶1:1 ratio for each arm, and patients were assigned to 
one of the 3 groups. The researchers conducting that pro-
cess did not participate in the evaluation of the results. 
It should be emphasized that all the patients were under 
osteoarthritis control through the standard treatment 
with NSAIDs prescribed by their family physician before 
they entered the study.
Arthroplasty procedure
All surgeries were performed by the same skilled surgi-
cal team and under subarachnoid anesthesia. A medial 
parapatellar approach was used to expose the knee joint. 
An inflatable tourniquet was attached to the limb with a 
pressure of 100 mmHg above the systolic blood pressure. 
An intramedullary alignment jig was used for the dis-
tal femoral resection, and an extramedullary device was 
used for the tibia. The implant employed was a cemented 
total knee prosthetic component (Vanguard Knee System 
Biomet, Warsaw, Indiana, USA) with no patellar resur-
facing that substituted the posterior cruciate ligament. 
In the treatment group, the femoral hole was sealed with 
an autologous bone plug obtained from bone off-cuts and 
cement. Subcutaneous skin closure was then performed. 
The tourniquet was deflated, after application of a com-
pressive elastic bandage. A dose of 40 mg of enoxaparin 
was administered subcutaneously to all patients at 22  h 
post-surgery and then daily, until discharge. The patients 
had a drainage tube that was removed 24 h after the pro-
cedure. Active isometric quadriceps movements, straight 
leg raises, and extension–flexion motions were encour-
aged 48  h after the surgery. All patients were released 
from the hospital at 48–72 h after surgery. The patients 
were programmed for transfusion if their Hb levels 
dropped below 80 g/L with symptoms of syncope, fatigue, 
and/or palpitations. The skin sutures were removed 
10 days after surgery and walking with the aid of a walker 
was indicated. The patients were referred to the physio-
therapy and rehabilitation service. They continued to see 
their family physicians for general care, healthy lifestyle 
promotion, and when necessary, to continue with NSAID 
pharmacologic treatment. The researchers did not inter-
vene in the prescription of drugs or lifestyle indications.
BIOF2 administration
BIOF2 is a patented formulation composed of a corticos-
teroid, a type of insulin, and organic acids, whose intra-
articular application is intended to stimulate cartilage 
regeneration. The BIOF2 manufacturing process was 
performed according to Good Manufacturing Practices 
(GMP) for pharmaceutical products for use in clinical tri-
als by Esteripharma Mexico (Mexico City, Mexico).
BIOF2 was administered on three occasions, with 
3-month intervals (at months 0, 3, and 6). It was an out-
patient application performed at the traumatology and 
orthopedics consultation office. BIOF2 treatment was 
administered as an injection into the knee joint space 
under sterile prep conditions, (i.e., prior to injection, the 
knee was cleaned with an antiseptic). The patient was in 
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a seated position, with the knee undergoing treatment 
flexed at 0°. The area of injection was inferior lateral to 
the patella at the lateral level of the joint line. The prin-
cipal investigator decided whether it was appropriate to 
apply local anesthesia with lidocaine. A 20-gauge nee-
dle 1.5 in long was used for the injection. The needle 
was passed through the fat pad to the firm surface of 
the intercondylar notch. Following needle withdrawal, 
pressure was applied with a cotton ball with alcohol at 
the injection site, which was then covered with a sterile 
dressing (BandAid). The patients continued to carry out 
their daily activities after the procedure, with no special 
indications, and were referred to the physiotherapy and 
rehabilitation service. They continued to see their family 
physicians for general care, healthy lifestyle promotion, 
and when necessary, to continue with NSAID pharmaco-
logic treatment. The researchers did not intervene in the 
prescription of drugs or lifestyle indications.
Standard conservative treatment with NSAIDs
That patient group continued with their treatment as 
prescribed by their family physicians. Treatment con-
sisted of NSAID administration and the promotion of a 
healthy lifestyle. The researchers did not intervene in the 
prescription of drugs or lifestyle indications. The patients 
were referred to the physiotherapy and rehabilitation ser-
vice. It was written in the case record that the patients 
were candidates for arthroplasty and they were told they 
could opt for surgery at any time during the study fol-
low-up, depending on their wishes and the possibility of 
access to government programs for knee replacement or 
by means of their own resources.
Outcome measures and follow‑up
The primary endpoint was the change in WOMAC score 
to ≤ 29 at months 3 and 6, and ≤ 16 points at month 12. 
Treatment of total joint arthroplasty, taken as the gold 
standard for treatment of severe osteoarthrosis of the 
knee, was considered successful with that score [21]. The 
WOMAC instrument has a total score and subscales for 
stiffness, pain, and physical function [22].
The secondary endpoints included:
a) Change in the Routine Assessment of Patient Index 
Data 3 (RAPID3), which is a pooled index of the 
three patient-reported Core Data Set measures of the 
American College of Rheumatology: physical func-
tion, pain, and patient estimate of global status. The 
RAPID3 instrument has a final score of 0 to 10 that 
was interpreted as near remission (0–1), low severity 
(1.3–2), moderate severity (2.3–4), and high sever-
ity (4.3–10). Although it is mainly used in rheumatic 
diseases, it is considered to be useful for evaluating 
osteoarthritis [23, 24]. Treatment was considered 
successful with a score of 2 or less.
b) Change in the Rasmussen clinical score. It pro-
vided a record of functional results of the joint after 
treatment. A score of 28–30 was excellent, a score 
of 24–27 was good, a score of 20–23 was fair, and 
a score of < 20 was poor [25]. Treatment was con-
sidered successful with a score of 24 or more and a 
change in the daily use of NSAIDs at 1 year of pro-
gression.
c) Change in NSAID consumption. All the patients 
were under osteoarthritis control through the stand-
ard treatment with NSAIDs prescribed by their fam-
ily physician before they entered the study. NSAID 
consumption during the entire study was monitored 
by the researchers through anamnesis.
The primary and secondary endpoints were deter-
mined at the baseline and at months 3, 6, and 12 after the 
beginning of treatment.
The area of articular cartilage of the knee was evalu-
ated in the BIOF2 group before treatment and at month 
12 of treatment, through three-dimensional cartilage 
reconstruction from magnetic resonance imaging (MRI) 
studies. MRI was performed using a clinical 1.5T magnet 
(Magnetom Expert; Siemens Healthcare GmbH, Erlan-
gen, Germany) and a circular polarized transmit–receive 
extremity coil. To obtain high-contrast and high-resolu-
tion images of the cartilage, a T1-weighted spoiled 3D 
gradient-echo sequence was used (fast low-angle shoot 
sequence with selective water excitation, radiofrequency 
amplitude ratios 1-2-1, repetition time 19 ms, echo time 
8.6 ms, flip angle 20°, and bandwidth 130 Hz/pixel). The 
partition thickness was 5 mm and the in-plane resolution 
was 0.31 mm (field of view 160 mm, matrix 5122 pixels, 
phase resolution 100%, and slice resolution 75%). One 
coronal, sagittal, and axial data set of the tibiofemoral 
joint and of the patellofemoral joint were acquired. The 
data were then transferred to a work station for analy-
sis using the ECLIPSE Versinn 11.0 software, designed 
by Varian Medical Systems (Palo Alto, CA, USA). In all 
the axial MRI images, the bone and cartilaginous struc-
tures were first separately defined. Afterwards, the axial 
views were joined, interpolating one view with another, 
to create a continuous 3D structure of the region of the 
knee. The coronal and sagittal views of the joint were 
also reconstructed. The volume of the cartilage  (cm3) was 
obtained using ECLIPSE algorithm tools.
In the BIOF2 group, the safety of the procedure was 
measured by the appearance of pain or serum marker 
alterations of: systemic inflammation (erythrocyte 
sedimentation rate, C-reactive protein, and fibrino-
gen), serum lipids (total cholesterol and triglycerides), 
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complete blood count, and liver function tests or kidney 
function tests. Those parameters were evaluated at base-
line, at 72 h, and at months 1, 3, 6, and 12. The delayed 
adverse effects of infection, muscular atrophy, profound 
venous thrombosis, hematoma, tissue hypertrophy, 
formation of adhesions, or systemic reactions, such as 
abdominal pain/discomfort, were evaluated in all groups.
Blinding
Only the researchers that evaluated treatment effective-
ness through the WOMAC, RAPID3, and Rasmussen 
clinical score instruments, those that carried out the 
anamnesis in relation with NSAID consumption, and the 
researchers that performed the statistical analyses were 
blinded.
Sample size
The sample size calculation was based on the difference 
(60%) in the number of patients with a successful result (a 
WOMAC score ≤ 16) at 1 year, between the BIOF2 group 
and the group that received the standard conservative 
treatment with NSAIDs. Eight patients from each group 
were needed to reach the required power (0.8) when the 
statistical analysis was performed at the level of the two-
tailed alpha (0.05). At the end of the study, the statistical 
power for detecting a difference between two different 
groups was calculated (alpha = 0.05), utilizing the num-
ber of patients with therapeutic success at 12  months 
between the BIOF2 group and the NSAID group, and its 
result was 96.4%.
Statistical analysis
Data were presented as percentages or mean ± standard 
error or standard deviation. For the inferential statistics, 
normal data distribution was first determined using the 
Kolmogorov–Smirnov test and the equality of variances 
was confirmed using the Levene’s test. One-way ANOVA 
with Bonferroni’s post hoc test was employed to com-
pare the numerical variables (with normal distribution) 
between the three groups (BIOF2, NSAIDs, and arthro-
plasty). The categorical values were compared using 
the Fisher’s exact test. The area of articular cartilage of 
the knee (MRI evaluations), serum markers, and com-
plete blood counts of the patients in the BIOF2 group 
was compared before and after treatment, utilizing the 
paired Student’s t test. The treatment success percentage 
(WOMAC score ≤ 29 points at months 3 and 6 and ≤ 16 
points at month 12; Rasmussen clinical score ≥ 24 points, 
and RAPID3 score ≤ 2 points) was calculated for the dif-
ferent treatments at months 3, 6, and 12. The comparison 
of two data series, such as cartilage volume before and 
after treatment, was carried out using the paired Stu-
dent’s t test. The Pearson correlation coefficient (r) was 
employed to correlate articular cartilage volume or its 
increase in percentage with the WOMAC score, RAPID3 
score, and the Rasmussen clinical score. The relative risk 
(RR) and 95% confidence interval were calculated to 
determine the probability of habitual NSAID use, com-
paring the NSAID group vs the BIOF2 group or arthro-
plasty group. The statistical analysis was performed using 
the SPSS software, version 20 (IBM Corp., Armonk, NY, 
USA), with the exception of the RR, which was calculated 
using the MedCalc v17.7.2 software (MedCalc Software 
bvba, Ostend, Belgium). A two-sided P < 0.05 was consid-
ered statistically significant.
Results
Of the 58 patients that were screened, 24 were rand-
omized and distributed into the three study groups (see 
Additional file 1). Table 1 shows the patient clinical char-
acteristics at the beginning of the study. All the patients 
completed the 1-year follow-up.
Figure  1a shows the success percentages with the dif-
ferent treatments. Arthroplasty reached high success 
rates at month 3 and both BIOF2 and arthroplasty had 
important success percentages starting at month 6 (suc-
cess in ≥ 75% of the patients at month 6, according to the 
WOMAC score). At month 12, there were no statistically 
significant differences in the evaluated scores between 
the BIOF2 group and the arthroplasty group. Figure  1b 
shows patient progression according to the WOMAC 
subscales for pain, stiffness, and physical function. No 
changes in any of the subscales were produced over time 
in the NSAID group. In contrast, the BIOF2 group and 
arthroplasty group had significant improvement in the 
three subscales over time. Additional file 2 shows the val-
ues of the WOMAC, Rasmussen, and RAPID3 scores of 
the three groups throughout the 1 year of follow-up.
Table 1 Distribution of  the  main clinical characteristics 
of the subjects at the beginning of the study
Percentages or averages and standard deviation are shown. BMI body mass 
index.* Fisher’s exact test; **One‑way ANOVA
Clinical 
characteristic
Arthroplasty NSAIDs BIOF2 P
Men (%) 50.0% 62.5% 50.0% 0.84*
Age (years) 62.8 ± 8.6 68.0 ± 7.1 68.5 ± 8.9 0.34**
BMI 29.5 ± 2.9 29.8 ± 2.1 28.0 ± 3.3 0.41**
Smoking 37.5% 25.0% 25.0% 0.81*
Diabetes 37.5% 25.0% 12.5% 0.51*
High blood pressure 62.5% 37.5% 50% 0.60*
WOMAC 73.3 ± 15.2 61.6 ± 16.0 62.7 ± 21.6 0.366**
Rasmussen 15.0 ± 7.0 14.0 ± 2.2 12.7 ± 3.6 0.643**
RAPID3 7.0 ± 1.5 8.3 ± 0.6 7.4 ± 1.1 0.103**
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At the beginning of the study, 100% of the patients 
in the three groups required NSAIDs on a daily basis. 
They took from 2 to 3 different drugs to control their 
pain. Sixty-seven percent took paracetamol, 62% took 
diclofenac, 46% took ketorolac, 17% took naproxen, 17% 
took celecoxib, 8% took ibuprofen, and 12% took tram-
adol. At month 12 of the follow-up, 75% of the patients 
with BIOF2 and 75% of the patients with arthroplasty no 
longer required NSAID use. That reduction in NSAID 
consumption was statistically significant for both the 
BIOF2 group and the arthroplasty group, compared 
with the group that exclusively took NSAIDs (RR = 0.33, 
95% CI 0.12–0.87, P = 0.02. This result was the same for 
BIOF2 vs NSAIDs and arthroplasty vs NSAIDs). At the 
end of the study, only two patients (25%) from the arthro-
plasty group and two patients (25%) from the BIOF2 
group required habitual use of NSAIDs, whereas 100% 
the patients in the NSAID group required them daily.
Articular cartilage volume was a success parameter 
evaluated in the 8 patients of the BIOF2 group. Total 
articular cartilage was significantly increased by 22% 
at 1  year of treatment (26.16 ± 10.0 vs 31.96 ± 10.0  cm2, 
P < 0.001), with a range of 10 to 43%. The 6 patients with 
therapeutic success had at least a 20% increase in car-
tilage. The two patients in the BIOF2 group with failed 
treatment (according to the WOMAC score) were the 
patients that had the least increase of cartilage (18 and 
10%). Even though those two patients did not reach 
scores considered therapeutic success, they reduced 
their WOMAC scores by 48 and 18%, respectively, at 
month 12. Figure  2 shows nuclear magnetic resonance 
images of the knee joint of the patient with the greatest 
cartilage growth, before and after treatment with BIOF2. 
Figure  3 shows the three-dimensional reconstruction of 
the knee of said patient. Articular cartilage volume was 
not correlated with the WOMAC score prior to treat-
ment (r = − 0.37, P = 0.40) or at month 12 (r = − 0.46, 
P = 0.28). However, the percentage of increased carti-
lage had a reverse correlation with the WOMAC score at 
12 months of treatment (r = − 0.75; P = 0.03). There was 
no correlation between the increase in cartilage and the 
RAPID3 score or the Rasmussen clinical score.
With respect to adverse effects, the patients presented 
with local pain in the joint after BIOF2 application of an 
Fig. 1 Clinical progression of patients over 12 months, according to the different scales for evaluating osteoarthritis. a Percentages of patients with 
successful treatment over time, according to the different evaluation scales are shown (scores: WOMAC ≤ 29 at 3 and 6 months and ≤ 16 points 
at 12 months, Rasmussen clinical score ≥ 24, RAPID3 ≤ 2). None of the patients in the NSAID group had treatment success. At month 6, 75% of 
the patients treated with BIOF2 had treatment success, according to the WOMAC scale. At month 12, the treatments with BIOF2 and arthroplasty 
showed no statistically significant differences, according to all the scales. b WOMAC subscales for pain, stiffness, and physical function. The group 
treated exclusively with NSAIDs had no changes over time. The treatments with BIOF2 and arthroplasty produced significant changes over time in 
all the subscales (one‑way ANOVA test P < 0.05, for both groups). Mean and standard error were plotted
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Fig. 2 Nuclear magnetic resonance images of the knee joint before and after treatment with BIOF2. Axial views at the height of the patella (a, b) 
and the femoral condyles (c, d) and coronal views (e, f), before and after 12 months of treatment, respectively. The arrows indicate the zones in 
which treatment generated a beneficial change, with respect to cartilage thickness or continuity. 1: cartilage, 2: femur, 3: patella 4: femoral condyle, 
5: muscle, 6: tibia
Fig. 3 Three‑dimensional reconstruction of the knee joint before and after 12 months of treatment with BIOF2. It shows the bone region (yellow) 
and cartilaginous region (white) of the joint in an anterolateral view (a, b) and a posterior view (c, d). The image corresponds to the patient that had 
the greatest increase in cartilage (43%). Femur and tibia cartilage fusion observed in some regions of the a or b images, corresponds to a defect 
in the three‑dimensional reconstruction, in which the virtual space between the two structures, at that point in particular, was not able to be 
distinguished
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intensity of 8.2 ± 0.4 (visual analogue scale of 0 to 10) and 
lasting 53 ± 45 s. In some cases, the pain radiated to the 
pelvis, but it ceded spontaneously. Toxicity tests were 
performed in the BIOF2 group at 72  h and at months 
1, 3, 6, and 12. No serum alterations were found in the 
liver enzymes (ALT, AST, LDH, ALP, bilirubin, and albu-
min), glucose, creatinine, uric acid, urea, or electrolytes 
(Na, K, and Cl). The complete blood count showed leu-
kocytes (due to neutrophils) above the normal limits in 
two patients at 72  h that returned to baseline levels at 
month 1 of treatment and was not associated with abnor-
mal signs and symptoms. Serum inflammation markers 
decreased at 3  days of treatment, compared with their 
baseline levels and the erythrocyte sedimentation rate 
(286 ± 38 vs 249 ± 20, P = 0.001), fibrinogen (25.3 ± 5.0 vs 
19.12 ± 6.0, P = 0.04), and C-reactive protein (1.6 ± 0.7 vs 
1.1 ± 0.9, P = 0.01) returned to baseline values at month 
1 of treatment. Interestingly, total cholesterol levels were 
significantly reduced, with respect to the baseline val-
ues, at 1 year of treatment (215 ± 40 vs 188 ± 8, P = 0.02), 
as were the triglyceride levels (240 ± 83 vs 151 ± 41, 
P = 0.01). The patients that underwent arthroplasty did 
not present with adverse effects, other than those nor-
mally expected after surgery. Six patients in the NSAID 
group (75%) presented with abdominal pain/discomfort 
at some point during follow-up, which was the reason 
the family physicians prescribed H2-blockers or pro-
ton pump inhibitors to all the patients of that group at 
the end of the follow-up period, to prevent severe acute 
NSAID-related gastroduodenal damage.
Discussion
The intra-articular application of a new bioactive formu-
lation, called BIOF2, demonstrated therapeutic efficacy 
that was clearly superior to conservative treatment with 
NSAIDs for the treatment of severe osteoarthritis of the 
knee. In addition, there was no statistically significant dif-
ference in its success rate, with respect to that of arthro-
plasty. Treatment success was accompanied by articular 
cartilage regeneration, with an increase of at least 20% in 
relation with pre-treatment cartilage volume. Therapeu-
tic efficiency was tested through three scoring instru-
ments that evaluated pain, functionality, and quality of 
life of the patients with osteoarthritis. Treatment with 
BIOF2 began to produce significant improvement at 
month 3.
It has previously been demonstrated in three differ-
ent animal models that hyaline cartilage regeneration 
may be induced in  vivo via the intra-articular applica-
tion of BIOF2. A trial in an animal model showed that 
the thickness of the cartilage and the number of chon-
drocytes began to increase slightly on post-treatment day 
14, and very significantly on day 28. Articular cartilage 
regeneration, stimulated by BIOF2, has now been dem-
onstrated in humans. The cartilage of the knee increased 
22% on average at month 12 of treatment, accompanied 
by significant clinical improvement starting at month 
3. That is an important increase in cartilage. A previous 
study showed that when patients had severe osteoarthri-
tis of the knee (identified through elevated WOMAC 
scores: 46 ± 6.2), they also presented with a rapid loss 
of articular cartilage mass (6.4 ± 0.7% at 12  months) 
[26]. Such cartilage loss is significantly higher than that 
experienced by patients with mild osteoarthritis [26]. 
Therefore, patients with severe osteoarthritis of the knee 
were catalogued as fast progressors in that study [26]. 
Our group treated with BIOF2 had WOMAC scores of 
62.7 ± 21 at the beginning of the study, and so could be 
considered fast progressors [26]. Those patients did not 
lose cartilage, but rather had an increase of cartilage at 
month 12, showing that BIOF2 not only stopped the nat-
ural progression of the osteoarthritis, with respect to car-
tilage loss, but also reversed it to varying degrees.
Total cartilage volume did not correlate with the 
WOMAC score at the beginning or at the end of the 
study, but the cartilage increment percentage correlated 
with the WOMAC score at the end of the study. Thus, it 
can be supposed that the changes in articular cartilage 
volume were those related to the symptomatology of 
the patients and not to the net cartilage volume that the 
patient had at the end of treatment. The elevated corre-
lation index between the post-treatment WOMAC score 
and the cartilage increment percentage could be clinically 
useful. In patients treated with cartilage regenerating 
substances, it could be assumed that a lower post-treat-
ment WOMAC score would signify a greater increase in 
cartilage, eliminating the need for complex studies, such 
as nuclear magnetic resonance. Nevertheless, further 
studies on that topic are required.
BIOF2 is composed of a corticosteroid, a type of insu-
lin, and organic acids. Corticosteroids are bioactive 
substances, but when acting alone, may facilitate tissue 
atrophy and joint destruction. However, when acting in 
synergy with the other factors in BIOF2, they can pro-
duce chondrogenesis. It has been proposed that BIOF2 
modifies the intra-articular microenvironment to stimu-
late articular regeneration, by generating molecular and 
morphologic alterations in synovial fluid cells and chon-
drocytes. In human synovial cells, BIOF2 increases the 
expression of SOX9, a transcription factor that is essen-
tial for chondrocyte differentiation and cartilage forma-
tion [27, 28]. It also causes reduced expressions of the 
macrophage-stimulating protein receptor (MST1R) and 
mimecan (OGN). OGN has been reported to be ele-
vated in osteoarthritis synovial fluid samples and may 
induce the mineralization and calcification of cartilage 
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[29]. MST1R has been previously associated with osteo-
clastogenesis, osteolysis, and inflammation [30, 31]. The 
above data demonstrate a mechanism of action of BIOF2 
that is consistent with the clinical results encountered.
It is clear that treatment of severe osteoarthritis of 
the knee with BIOF2 has advantages, compared with 
conservative treatment with NSAIDs, and could be 
an effective alternative to total joint arthroplasty. It is 
also a more economic and less complex procedure than 
arthroplasty, especially for patients of advanced age and/
or those with comorbidities. In addition, BIOF2 signifi-
cantly reduced NSAID use. Prolonged NSAID use can 
cause adverse effects, especially kidney damage [32]. 
Thus, treatment with BIOF2 could also help patients 
reduce the risks involved in the long-term use of those 
medications. Treatment with BIOF2 can be applied in an 
outpatient setting at a consultation office, taking the cus-
tomary precautions for any intra-articular injection. The 
only adverse effect detected was pain upon application, 
and although intense, it spontaneously remitted within 
seconds or a little over a minute. Arthroplasty efficacy in 
our study was 75%. The panorama for improving qual-
ity of life is complex in patients with therapeutic failure 
after arthroplasty. In contrast, in patients with therapeu-
tic failure after BIOF2 application, they could still opt to 
undergo the customary therapeutic alternatives, from 
viscosupplementation to arthroplasty.
Other clinical trials have evaluated articular cartilage 
regeneration through cellular therapy in the repair of 
defects in knee cartilage in young persons [33], in mod-
erate osteoarthritis [34], in severe osteoarthritis [35], 
and in avascular bone necrosis [36] [37], mainly with 
positive results. Other procedures include implants uti-
lizing novel biomaterials [38] and the use of genetically 
engineered chondrocytes [39], with varying degrees of 
effectiveness. However, unlike our study, none of those 
trials compared the efficacy of the procedures with total 
joint arthroplasty. Procedures with stem cells involve 
complex strategies that are costly and difficult to imple-
ment in medical centers. In addition, problems still exist 
that must be resolved in the future, including limited cell 
availability, the numerous surgical procedures involved, 
or in vitro chondrocyte dedifferentiation or cell propaga-
tion [11]. Therefore, we consider that treatment with the 
new bioactive cell-free formulation (BIOF2) is a promis-
ing and easily implemented option for the treatment of 
osteoarthritis or pathologies with articular cartilage loss 
due to other causes.
It is striking that in the patients treated with BIOF2, 
total cholesterol and triglyceride levels were significantly 
reduced at 1  year. It has been proposed that osteoar-
thritis of the knee affects mobility, mood, and sleep pat-
terns, and reduces physical fitness, with an increase in 
cardiometabolic comorbidity [3, 5–7, 40]. Therefore, it 
is likely that patients treated with BIOF2, upon recover-
ing their quality of life, have greater physical activity, thus 
reducing their cardiovascular risks, reflected in reduced 
serum lipids. However, a limitation of our study was the 
fact that serum markers or MRI evaluations were not car-
ried out in the arthroplasty group or the NSAID group, 
and so we were not able to compare results with those 
of the BIOF2 group. The low number of patients and the 
1-year follow-up period were other limitations of the 
present study and are aspects that must be considered in 
future analyses to broaden the knowledge about this new 
treatment.
Conclusions
The intra-articular application of a new bioactive cell-
free formulation, called BIOF2, was shown to be well 
tolerated, with a success rate that showed no statistically 
significant difference from that of arthroplasty for the 
treatment of severe osteoarthritis of the knee. Success 
is most likely related to articular cartilage regeneration. 
BIOF2 has great potential for use in osteoarthrosis as an 
easily implemented therapeutic alternative.
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